stocks logo

ADPT Valuation

Adaptive Biotechnologies Corp
$
13.180
-0.13(-0.977%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

ADPT Relative Valuation

ADPT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADPT is overvalued; if below, it's undervalued.
Intellectia AI SwingMax

Historical Valuation

Adaptive Biotechnologies Corp (ADPT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.90 is considered Undervalued compared with the five-year average of -12.61. The fair price of Adaptive Biotechnologies Corp (ADPT) is between 538.70 to 542.15 according to relative valuation methord. Compared to the current price of 13.13 USD , Adaptive Biotechnologies Corp is Undervalued By 97.56%.
Relative Value
Fair Zone
538.70-542.15
Current Price:13.13
97.56%
Undervalued
-19.97
PE
1Y
3Y
5Y
Trailing
Forward
-78.78
EV/EBITDA
Adaptive Biotechnologies Corp. (ADPT) has a current EV/EBITDA of -78.78. The 5-year average EV/EBITDA is -18.02. The thresholds are as follows: Strongly Undervalued below -51.92, Undervalued between -51.92 and -34.97, Fairly Valued between -1.06 and -34.97, Overvalued between -1.06 and 15.89, and Strongly Overvalued above 15.89. The current Forward EV/EBITDA of -78.78 falls within the Strongly Undervalued range.
-20.56
EV/EBIT
Adaptive Biotechnologies Corp. (ADPT) has a current EV/EBIT of -20.56. The 5-year average EV/EBIT is -10.56. The thresholds are as follows: Strongly Undervalued below -30.15, Undervalued between -30.15 and -20.36, Fairly Valued between -0.77 and -20.36, Overvalued between -0.77 and 9.03, and Strongly Overvalued above 9.03. The current Forward EV/EBIT of -20.56 falls within the Undervalued range.
8.11
PS
Adaptive Biotechnologies Corp. (ADPT) has a current PS of 8.11. The 5-year average PS is 14.18. The thresholds are as follows: Strongly Undervalued below -17.13, Undervalued between -17.13 and -1.47, Fairly Valued between 29.83 and -1.47, Overvalued between 29.83 and 45.49, and Strongly Overvalued above 45.49. The current Forward PS of 8.11 falls within the Historic Trend Line -Fairly Valued range.
-45.85
P/OCF
Adaptive Biotechnologies Corp. (ADPT) has a current P/OCF of -45.85. The 5-year average P/OCF is -16.84. The thresholds are as follows: Strongly Undervalued below -47.37, Undervalued between -47.37 and -32.10, Fairly Valued between -1.58 and -32.10, Overvalued between -1.58 and 13.68, and Strongly Overvalued above 13.68. The current Forward P/OCF of -45.85 falls within the Undervalued range.
-579.08
P/FCF
Adaptive Biotechnologies Corp. (ADPT) has a current P/FCF of -579.08. The 5-year average P/FCF is -36.87. The thresholds are as follows: Strongly Undervalued below -207.42, Undervalued between -207.42 and -122.14, Fairly Valued between 48.41 and -122.14, Overvalued between 48.41 and 133.68, and Strongly Overvalued above 133.68. The current Forward P/FCF of -579.08 falls within the Strongly Undervalued range.
Adaptive Biotechnologies Corp (ADPT) has a current Price-to-Book (P/B) ratio of 11.27. Compared to its 3-year average P/B ratio of 3.39 , the current P/B ratio is approximately 233.03% higher. Relative to its 5-year average P/B ratio of 4.64, the current P/B ratio is about 142.74% higher. Adaptive Biotechnologies Corp (ADPT) has a Forward Free Cash Flow (FCF) yield of approximately -4.19%. Compared to its 3-year average FCF yield of -18.73%, the current FCF yield is approximately -77.62% lower. Relative to its 5-year average FCF yield of -14.34% , the current FCF yield is about -70.77% lower.
11.16
P/B
Median3y
3.39
Median5y
4.64
-4.09
FCF Yield
Median3y
-18.73
Median5y
-14.34
Financial AI Agent

Competitors Valuation Multiple

The average P/S ratio for ADPT's competitors is 1392.84, providing a benchmark for relative valuation. Adaptive Biotechnologies Corp Corp (ADPT) exhibits a P/S ratio of 8.11, which is -99.42% above the industry average. Given its robust revenue growth of 36.33%, this premium appears sustainable.
AI Stock Picker

Performance Decomposition

1Y
3Y
5Y
Market capitalization of ADPT increased by 180.43% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.34 to -16.21.
The secondary factor is the Revenue Growth, contributed 36.33%to the performance.
Overall, the performance of ADPT in the past 1 year is driven by P/E Change. Which is more unsustainable.
36.33%
43.19M → 58.88M
Revenue Growth
+
-59.40%
-107.08 → -43.47
Margin Expansion
+
203.50%
-5.34 → -16.21
P/E Change
=
180.43%
4.70 → 13.18
Mkt Cap Growth

FAQ

arrow icon

Is Adaptive Biotechnologies Corp (ADPT) currently overvalued or undervalued?

Adaptive Biotechnologies Corp (ADPT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.90 is considered Undervalued compared with the five-year average of -12.61. The fair price of Adaptive Biotechnologies Corp (ADPT) is between 538.70 to 542.15 according to relative valuation methord. Compared to the current price of 13.13 USD , Adaptive Biotechnologies Corp is Undervalued By 97.56% .
arrow icon

What is Adaptive Biotechnologies Corp (ADPT) fair value?

arrow icon

How does ADPT's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Adaptive Biotechnologies Corp (ADPT) as of Aug 30 2025?

arrow icon

What is the current FCF Yield for Adaptive Biotechnologies Corp (ADPT) as of Aug 30 2025?

arrow icon

What is the current Forward P/E ratio for Adaptive Biotechnologies Corp (ADPT) as of Aug 30 2025?

arrow icon

What is the current Forward P/S ratio for Adaptive Biotechnologies Corp (ADPT) as of Aug 30 2025?